Owkin Unveils AI-Driven Oncology and Immunology Pipeline, In-Licenses Best-in-Class Asset OKN4395

Contributed by: Business Wire

Logo

Tags

Technology

Research

Clinical Trials

Biometrics

Health

Pharmaceutical

Science

Artificial Intelligence

Oncology

science

More Like This

Owkin, an AI-Biotech Unicorn, Brings Its Cutting-Edge AI to Germany, Austria and Switzerland to Accelerate Research

Owkin enters collaboration agreement with MSD to develop AI-powered diagnostics for cancer

Owkin Announces Partnership with AstraZeneca to Develop an AI gBRCA Pre-Screen Solution for Breast Cancer

Owkin and Proscia Expand Access to AI Pre-Screening for Colorectal Cancer Patients

Oncocross Expands Collaboration with JW Pharmaceutical on Developing Innovative New Drugs Using AI in Anticancer and Regenerative Medicine

Owkin Announces MSIntuit® CRC v2, a Next-Generation AI Diagnostic Aimed at Transforming the Detection and Treatment of Colorectal Cancer

CORRECTING and REPLACING Jean-Jacques Bienaimé Appointed Chairman of the Board at Owkin

Evaxion Hosts R&D Day and Unveils the Broad Potential of Its AI-Immunology™ Platform